Skip to content
Screener

Vericel VCEL Total Equity

Total Equity at other companies

CONMED logo
CONMEDCNMD
$1.04B+3.8%
Anika Therapeutics logo
Anika TherapeuticsANIK
$137.28M-7.0%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$12.62B+0.8%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$420.34M+15.9%
MiMedx Group logo
MiMedx GroupMDXG
$216M-0.3%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
$148.27M-36.4%

Other financials

Income statement

See full
Revenue$77.5M+22.5%
Gross profit$56.4M+21.0%
Operating income$434.0K+121%
Net income$2.2M+499%
EPS (diluted)$0.04+500%

Balance sheet

See full
Cash & equivalents$125.4M+55.7%
Total debt$93.1M-7.3%
Total assets$502.9M+15.4%

Cash flow

See full
Operating cash flow$16.2M+97.1%
CapEx$1.9M-76.2%
Free cash flow$14.3M+17,504%

Valuation

See full
Market cap$2.31B+29.1%
Enterprise value$2.28B+25.9%
P/E95.3×-156×
P/S7.5×+0.4×

Profitability

See full
Gross margin74.6%+1.1pp
Operating margin6%+5.5pp
Net margin7.9%+5.1pp
FCF margin20.1%

Returns & leverage

See full
Return on equity7.2%+4.6pp
Debt / equity0.3×-0.1×
Current ratio+0.1×

Where this comes from

Reported directly by Vericel in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Vericel’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:49 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050836
Line itemJune 30, 2026December 31, 2025
Total liabilities132,825133,329
COMMITMENTS AND CONTINGENCIES (Note 12)
Shareholders’ equity:
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding — 51,171 and 50,620, respectively750,799730,662
Accumulated other comprehensive (loss) gain(365)275
Accumulated deficit(380,393)(376,297)
Total shareholders’ equity370,041354,640
Total liabilities and shareholders’ equity$502,866$487,969

Item 1. Financial Statements (Unaudited)

FAQ

What is Vericel's total equity?
Vericel (VCEL) reported total equity of $370.04M in Q2 2026.
How has Vericel's total equity changed year-over-year?
Vericel's total equity increased by 20.6% year-over-year, from $306.81M to $370.04M.
What is the long-term trend for Vericel's total equity?
Over 5 years (2020 to 2025), Vericel's total equity has grown at a 21.4% compound annual growth rate (CAGR), from $134.26M to $354.64M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Vericel's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude